# Knowledge, attitudes and practices of doctors regarding isoniazid preventive therapy in HIV/AIDS patients at Odi District Hospital, Gauteng province, South Africa

## AT Abdulrazaak (), I Govender\* and D Nzaumvila

Department of Family Medicine and Primary Health Care, Sefako Makgatho Health Sciences University, Pretoria, Gauteng, South Africa

\*Corresponding author, email: indiran.govender@gmail.com

Check for updates

**Introduction:** Isoniazid preventive therapy (IPT) can reduce the overall risk of active tuberculosis (TB) in people living with HIV/ AIDS (PLHIV) by up to 62%. As a result the World Health Organization (WHO) and the Joint United Nations Programme on HIV/ AIDS (UNAIDS) have recommended IPT provision as a global strategy to reduce the prevalence of TB for PLHIV. However, whilst there are 84 countries supporting the provision of IPT in their policies, less than 1% of PLHIV in those countries are currently receiving IPT. Approximately 65% of TB patients in South Africa are HIV co-infected. Despite this fact, doctors are hesitant to prescribe IPT to TB-negative HIV-infected patients. Many doctors are also unaware of the current IPT guidelines of South Africa. This study sought to determine the level of knowledge, attitudes and practices of doctors regarding IPT for patients infected with HIV at Odi Hospital in Gauteng.

Methods: A cross-sectional descriptive study was undertaken with a standardised questionnaire administered to 51 doctors working at Odi Hospital.

**Results:** There were 51 respondents, many doctors (43.1%) having an excellent knowledge of IPT. Although one-third of the doctors were dispassionate about IPT provision, the majority of respondents (54.9%) had positive attitudes towards IPT provision. On average the doctors had good practices regarding IPT provision (35.3%). There were 12 (23.5%) doctors who were trained for IPT implementation. Although training was not associated with doctors' knowledge or attitudes towards IPT, it was associated with the practice of IPT implementation.

**Conclusion:** Irrespective of their position, doctors at Odi District Hospital need formal training on the implementation of IPT, as this increases their confidence in IPT and their implementation practices.

Keywords: district hospital, HIV/AIDS, isoniazid preventive therapy, tuberculosis

## Introduction

The World Health Organization (WHO) estimates that there are more than 1 000 HIV-infected people dying every day from tuberculosis (TB).<sup>1</sup> In 2015 the incidence of TB was 10.4 million cases worldwide and, of these, 1.2 million people were coinfected with HIV. During the same year, mortality from TB was 1.6 million people worldwide, with 400 000 people coinfected with HIV.<sup>2</sup> Africa is the continent with the highest prevalence of TB and HIV and 79% of TB patients living in Africa are HIV-positive.<sup>2</sup> In order to address the number of deaths caused by TB and HIV co-infection, the 'Three I's' strategy was proposed by the WHO: (i) intensify case findings, (ii) provide isoniazid preventive therapy (IPT), and (iii) control both infections.<sup>3</sup> IPT provision has been successful in preventing new cases of TB in many countries.<sup>4</sup>

IPT is the administration of isoniazid (INH) to individuals with latent TB infection in order to prevent progression to active TB disease. INH is one of the most effective bactericidal anti-TB drugs available. INH not only protects against progression of latent TB infection to active disease, i.e. reactivation, but also prevents TB reinfection after exposure to an active case of TB. People living with HIV/AIDS (PLHIV) must be screened for TB using a four-symptom complex (current cough or fever or weight loss or night sweats) at HIV care settings, and those with any of these symptoms should be evaluated to rule out active TB.<sup>5</sup>

HIV-infected people are at a high risk of developing active TB, and are therefore provided with INH. It should, however, be confirmed that they do not have active TB before starting IPT. According to the WHO the risk of active TB in PLHIV can be reduced by up to 62% with the use of IPT.<sup>3</sup> IPT may be provided as a safe, effective and feasible strategy for PLHIV in geographical regions with high rates of latent or highly active TB prevalence.<sup>5,6</sup> When IPT is given for six months, the burden of TB on PLHIV is reduced from 67% to 33%.<sup>7</sup> The SA IPT guidelines recommend at least 36 months of IPT for TST-positive HIV-infected persons, including people on ART; 6 months of IPT for those whose TST status is unknown, regardless of whether they are on ART or not; and 12 months of IPT for persons on ART if their TST is negative (NDOH, 2013).<sup>8</sup> However, in a randomised control trial by Churchyard et al. (2014),<sup>9</sup> it was found that a nine-month course of community-wide isoniazid preventive therapy did not improve tuberculosis control in South African gold mines. Continuous isoniazid preventive therapy should be considered for persons at highest risk for tuberculosis (i.e. those with HIV infection or silicosis) along with strategies to maximise retention.<sup>10</sup>

Jointly the United Nations Programme on HIV/AIDS (UNAIDS) and WHO made recommendations for the provision of IPT as a global strategy to reduce the incidence of TB for PLHIV.<sup>11</sup> However, whilst there are 84 countries with clear policies on IPT, less than 1% of PLHIV in those countries are currently receiving IPT.<sup>12</sup>

Although TB is a global health problem, the prevalence of TB/HIV co-infection is highest in South Africa with approximately 65% of TB patients also living with HIV.<sup>13</sup> Despite this fact, a recent study suggests that doctors are hesitant to prescribe IPT to TB-negative but HIV-infected patients. This contributes to the national TB epidemic. Substantial anecdotal evidence shows that doctors in South Africa have not been conforming to the WHO recommendations for prescribing IPT.<sup>1</sup> In 2014, 1 299 patients were initiated on antiretroviral therapy (ART) at Odi Hospital, but only 520 of these patients were initiated on IPT. A similar picture could be seen at the end of the third quarter of 2015 when 557 patients were initiated on ART, but only 295 were initiated on IPT.<sup>14</sup> South African doctors either fear or are ignorant of IPT, despite IPT being recommended by the South African Department of Health.<sup>15</sup>

In Ethiopia lack of IPT implementation by healthcare providers was associated with the lack of opportunities for training on IPT and the unavailability of guidelines. Other reasons given by healthcare providers for not prescribing IPT were a lack of experience and not being aware of IPT efficacy.<sup>16</sup> Although the WHO and South African National Department of Health issued key intervention guidelines and recommendations, the provision of IPT still lags behind in South Africa. Barriers preventing IPT implementation encompass a lack of training opportunities, fear of resistance to INH, unavailability of INH and INH's side effects.<sup>17</sup>

## Methodology

This was a cross-sectional descriptive study that used a standardised self-administered questionnaire (see Appendix).

Odi district hospital is a level one hospital located in Mabopane, which is a border town in Gauteng province, 45 km north of Tshwane, South Africa. This is a 198-bed district hospital that serves a population of 524 632 people from Gauteng province and 355 905 people from North West province. The hospital has a large referral network of numerous clinics from both provinces, and is divided into service delivery units that include outpatients, emergencies, maternity, and a wellness clinic which cares only for TB and HIV/AIDS patients. It provides for the healthcare needs of children and adults around Odi health sub-district.<sup>14</sup>

Most of the clients of this hospital are poor and unemployed. There is a diversity of people, with mostly South African citizens and some immigrants from many African countries; the majority of immigrants are from Southern African Development Community countries.

Odi District Hospital employs an average of 51 doctors.<sup>14</sup> All doctors working at Odi Hospital do rotate through the HIV clinic and hence all of them have encounters with TB and HIV/AIDS patients and do manage these patients. Information was collected from all of the doctors between September 1, 2015 and March 31, 2016. The different categories of doctors attending to patients with TB and HIV/AIDS were seen as relevant to the study and were included. Doctors were briefly orientated as to the reasons for the study. Doctors who consented to participate in the study were provided with the questionnaire, which was given to them after the daily morning meeting. At least four doctors were able to complete their questionnaire each morning. A list of all participants' names was recorded on a separate sheet, and to ensure confidentiality this list was kept in a safe place that only the researcher had access to.

The data collection was by using standardised self-administered questionnaires and these were analysed using the SAS 9.0 software package (SAS Institute, Cary, NC, USA). Data were primarily analysed using descriptive statistics. A relationship between categorical variables was calculated using a chi-square test. Fisher's exact test was used to determine the association between knowledge, attitude and practices of doctors and their sociodemographic characteristics, with statistical significance set at p < 0.05.

Permission to conduct this study was obtained from the Chief Executive Officer of Odi District Hospital. Data collection began after ethical clearance had been obtained from Sefako Mak-gatho Health Sciences University Research and Ethics Committee (SMUREC Ref. Number: SMUREC/M/202/2015; PG). Participation in the study was voluntary. Anonymity and confidentiality of the participants was maintained.

## Results

All 51 doctors working at Odi District Hospital completed the questionnaire, a response rate of 100%. This was achieved by meeting the doctors daily at the morning meetings to remind them of the study.

Table 1 gives demographic information on the participating doctors.

The response to each attitude statements by the doctors is given in Table 2. A total of 10 questions were asked in relation to the doctors' attitudes towards the efficacy and provision of IPT for PLHIV and nine of these questions were Likert scale options with positive statements ranging from strongly agree to strongly disagree.

Table 1: Doctors' sociodemographic characteristics

Characteristics		Frequency ( <i>n</i> = 51)	
Gender	Male	30	58.8
	Female	21	41.2
Age group (years)	20-34	18	35.3
	35–49	30	58.8
	50–64	2	3.9
	65–79	1	2
Age: Mean = 38 SD = 9	.46 Minimum = 23.0	0 Maximum	= 75.00
Professional category	Community service doctor	7	13.7
	Full-time medical officer	21	41.2
	Part-time medical officer	5	9.8
	Registrar	14	27.4
	Family physician	4	7.8
Experience (years)	≤ 9	37	72.5
	10–19	8	15.7
	20–29	3	5.9
	30–39	3	5.9
Experience: Mean = 9.2	SD = 7.7 Minimum	= 1.0 Maxim	um = 39.0
Additional formal training on HIV/TB	Training on TB and HIV	34	66.7
management or IPT	Training on IPT	12	23.5
	No formal training	5	9.8

Each of the above responses was regrouped into three by combining strongly agree and agree to (i) agree, undecided remained as (ii) undecided and strongly disagree and disagree was combined as (iii) disagree. Each correct answer was scored one and a wrong answer scored zero. The total score out of nine was then multiplied by 100 to find the percentage score for the attitude level as listed in Table 5. The scores were classified into three levels as follows:

Level	Definition
i.	Positive attitude: $\geq$ 75%;
ii.	Neutral attitude: 46%-74%;
iii	Negative attitude: $\leq$ 45%.

Table 3 shows the doctors' response to the practice of IPT questions. Ten questions were asked relating to the practices of doctors regarding the implementation of IPT according to national guidelines. Five of the questions enquired about the frequency with which doctors provide IPT to PLHIV, also measuring their adherence to the national and WHO guidelines. These five questions had multiple-choice options ranging from 'Yes always', 'Sometimes' and 'No'. The other five questions were open-ended questions asking about interventions required for successful implementation of IPT in the working areas of the doctors.

Bloom's cut-off point<sup>18</sup> was used to group the doctors' practice levels by measuring their provision of IPT and how its treatment management varied. The doctors' scores were from 0 to 5. The levels of their practice were grouped as follows:

Level	Definition
i.	Excellent: $\geq$ 75%;
ii.	Good: 46%-74%;
iii	Poor: ≤45%.

Table 4 shows the doctors' responses regarding individual knowledge of IPT. Doctors were asked a total of ten questions to explore their knowledge about IPT eligibility criteria, its management and IPT provision. One of the ten questions was openended to allow the doctors to express their ideas on the implementation of IPT at Odi District Hospital and the remaining nine questions were multiple-choice questions.

For each correct answer a mark was allocated and a percentage for the total marks was used to determine each doctor's

#### Table 3: Response to practice of IPT questions

Practice question	Yes, always	Sometimes	No
1. INH provision to HIV-positive patients	24 (47.06)	22 (43.14)	5 (9.80)
2. Management/monitoring of patients with INH drug toxicity	26 (50.98)	15 (29.41)	10 (19.61)
3. IPT eligibility is assessed with the use of TB screening tool (algorithm) as a criterion for PLHIV	26 (50.98)	21 (41.17)	4 (7.84)
4. Advice is given to patients regarding IPT adherence	45 (88.23)	6 (11.76)	0 (0.00)
5. PLHIV are encouraged to start IPT once eligible	26 (50.98)	24 (47.06)	1 (1.96)

knowledge. According to Bloom's taxonomy<sup>18</sup> cut-off points, the scores were grouped into three levels according to correct answers, as listed in Table 5: Excellent:  $\geq$  75% correct; Good: 46%–74% correct; Poor:  $\leq$  45% correct.

The overall knowledge was good with a mean score of 66.5% (SD = 16.6). Most of the doctors (43.1%) had excellent knowledge of IPT, whilst 37.3% had good knowledge and 19.6% poor knowledge of IPT.

A majority of the doctors (54.9%) had positive attitudes towards IPT, only 6 doctors had negative attitudes, whilst 17 (33.3%) were dispassionate about IPT provision. The global mean practice score of the doctors was 53.7% (SD = 23.7): 13 (25.5%) had excellent levels of practice, whilst 18 (35.3%) showed good practice levels, and the remaining 20 (39.2%) had poor practice levels with regard to IPT provision.

Table 6 gives the doctors' opinions of the barriers to successful implementation of IPT.

Comparison of possible associations between the knowledge, attitude, practices and sociodemographic characteristics of doctors was measured using Fisher's exact test. A *p*-value less than 0.05 was considered to be statistically significant.

There was no significant association between the doctors' experience and their knowledge, attitude and practices of IPT, as shown in Table 7.

Attitude statement	Strongly agree	Agree	Undecided	Dis agree	Strongly disagree
1. The risk of INH resistance can be significantly reduced with use of IPT after active TB was excluded.	15.7	54.9	15.7	11.8	2.0
2. IPT should be provided to children aged less than one year with a household history of TB case contact	32.7	59.2	2.0	4.1	2.0
3. Immune status in PLHIV should be a criterion for IPT eligibility	11.8	54.9	5.9	25.5	2.0
4. IPT should be offered to PLHIV who don't have night sweats, weight loss fever and current cough because they're unlikely to have active TB	22.0	58.0	10.0	8.0	2.0
5. You comply with national and international IPT recommendations	13.7	51	21.6	13.7	0.0
6. The reduction of TB mortality and incidence among PLHIV is effective by using IPT	33.3	52.9	3.9	9.8	0.0
7. Patients using IPT for longer periods have a reduced risk of TB	21.6	39.2	15.7	19.6	3.9
8. TB history is a contraindication for IPT provision	28.0	50.0	10.0	12.0	0.0
9. Pregnancy is a contraindication for IPT provision	51.0	39.2	7.8	2.0	0.0

#### Table 2: Response to each attitude statement

Table 4: Doctors' responses to individual IPT knowledge questions

	Correct	Percentage
Knowledge question	answers	(%)
1. The INH drug dose used for chemotherapy to prevent TB in an adult living with HIV	37	72.5
2. The combination of TB screening symptoms identifies PLHIV for IPT eligibility	45	88.2
3. IPT can be used as secondary prophylaxis for people with a past history of TB	26	51
4. Pregnancy is a contraindication for IPT eligibility	43	84.3
5. Assessment of patients' adherence to IPT	34	66.7
6. People eligible for IPT	22	43.1
7. The best preventative drug for TB	46	90.2
8. TB infection in HIV-positive patients can be reduced with the use of IPT	43	84.3
9. IPT eligibility is characterised by using chest radiography as a requirement for PLHIV screening	26	51

The *p*-value of 0.2986 indicates there was no statistically significant association between doctors' knowledge and attitude; however, 47% (n = 24) of the doctors with good and excellent knowledge scores also had a positive attitude towards IPT, as shown in Table 8.

There was no statistically significant association between knowledge and practice of the doctors towards IPT provision, with the *p*-value being 0.7352 (see Table 6). There is a significant association between the doctors' attitude and the practice of IPT, with a *p*-value of 0.0185, as shown in Table 9.

The results in Table 9 indicated that there is no statistical significance between training for IPT implementation and doctors'

Table 5: Composite doctors' knowledge, practices and attitude towards IPT

Knowledge	Number	Percentage		
Excellent ( $\geq$ 75%)	22	43.14		
Good (46-74%)	19	37.25		
Poor (≤ 45%)	10	19.61		
Total	51	100		
Knowledge: mean = 66.5 SD = 100.0	16.6 Minimum = 3	3.3 Maximum =		
Knowledge: mean = 66.5	SD = 16.6			
Level of practice	Number	Percentage (%)		
Excellent (≥ 75%)	13	25.49		
Good (46–74%)	18	35.29		
Poor (≤ 45%)	20	39.21		
Total	51	100		
Practice: mean = 53.7 SD = 23.	9 Minimum = 0 N	laximum = 100		
Attitude score	Number	Percentage (%)		
Positive ( $\geq$ 75%)	28	54.90		
Neutral (46–74%)	17	33.33		
Negative ( $\leq$ 45%)	6	11.76		
Total	51	100.0		
Attitude: mean = 71.7 SD = 17	.0 Minimum = 33.3	Maximum = 100.0		

Table 6: Barriers to successful implementation of IPT

Barrier	Number	Percentage (%)			
Lack of doctor's knowledge of IPT	19	37.3			
Fears of INH resistance	8	15.7			
Poor patient adherence	17	33.3			
Unavailability of INH	7	13.7			
Total	51	100			

knowledge or attitude, but that there is an association with doctors' practices regarding IPT provision, as evidenced by a p-value of 0.0185.

#### Discussion

When considering the demographic characteristics of this sample, most (89.5%) of the respondents were in the age group 22–40 years. In this regard, our results can be compared to a study where the context was similar.<sup>19</sup> More than half or 34 (66.7%) of the doctors had received formal training in managing patients with TB/HIV co-infection, and only 12 (23.5%) were trained on the IPT implementation programme.

Many doctors (22 or 43.1%) had excellent knowledge regarding the provision of IPT. These findings are in contrast with a large study done in Ethiopia, which indicated that efficient IPT implementation in that country was hindered by the healthcare providers' poor knowledge of IPT.<sup>20</sup> The high score in our study is most likely due to the formal training they received on TB/HIV and IPT. These findings are supported by a study conducted in Brazil, which reported that IPT training resulted in significantly increased knowledge of and prescription of IPT.<sup>21</sup>

The barriers to IPT implementation were reported by 37.3% of the doctors to be a lack of IPT knowledge and the possibility of poor patient adherence to IPT (33.3%). The most common researched barriers to IPT implementation are doctors' attitudes and beliefs.<sup>15</sup> A study in Thailand also found that doctors' fear of lack of patient adherence to IPT was a very common reason for their unsuccessful IPT implementation programme.<sup>22</sup> A South African study reported that patient adherence was not a concern for healthcare workers in prescribing IPT.<sup>20</sup> Thus it seems that doctors' knowledge of IPT and perceived poor adherence by patients due to possible side effects are barriers that can be overcome in South Africa, by training and effective implementation of the programme.

The fear of generating drug resistance was the third most common barrier to IPT implementation. This finding correlated with findings of a cross-sectional survey conducted by the WHO in 69 high-burden countries in 2007, which affirmed that doctors are sceptical of providing IPT despite efforts to exclude active TB and inadequate TB case findings.<sup>23</sup>

Unsuccessful provision of IPT by physicians was associated with inducing INH resistance in Thailand.<sup>24</sup> A systematic review assessing the effect of IPT on risk of INH-resistant TB reported that IPT increased the risk of INH resistance 1.45 times; this was not significant (relative risk 1.45; 95% confidence interval 0.85–2.47). The increased risk of INH-resistant TB is not excluded because of the relative risk and also because of the relatively small sample size, and the analysis was limited.<sup>25</sup> The consensus from current literature is that IPT does not promote INH resistance.<sup>26,27</sup>

		Experienc				
Knowledge of IPT	<b>≤</b> 9	10–19	20–29	30–39	Total	<i>p</i> -value
Excellent	17 (33.3)	3 (5.9)	0	2 (3.9)	22 (43.1)	0.2041
Good	12 (23.5)	4 (7.8)	3 (5.9)	0	19 (37.3)	
Poor	8 (15.7)	1 (2)	0	1 (2)	10 (19.6)	
Total	37 (72.5)	8 (15.7)	3 (5.9)	3 (5.9)	51 (100)	
Attitude:						
Positive	20 (39.2)	5 (9.8)	3 (5.9)	0	28 (54.9)	0.3335
Neutral	13 (25.5)	2 (3.9)	0	2 (3.9)	17 (33.3)	
Negative	4 (7.8)	1 (2)	0	1 (2)	6 (11.8)	
Total	37 (72.5)	8 (15.7)	3 (5.9)	3 (5.9)	51 (100)	
Practice:						
Excellent	9 (17.6)	2 (3.9)	2 (3.9)	0	13 (25.5)	0.5615
Good	12 (23.5)	3 (5.9)	1 (2)	2 (3.9)	18 (35.3)	
Poor	16 (31.4)	3 (5.9)	0	1 (2)	20 (39.2)	
Total	37 (72.5)	8 (15.7)	3 (5.9)	3 (5.9)	51 (100)	

#### Table 7: Relationship between doctors' experience and knowledge, attitude and IPT practices

#### Table 8: Relationship between doctors' knowledge, attitude and IPT practice

		Attitude			
Knowledge of IPT	Positive <i>n</i> (%)	Neutral <i>n</i> (%)	Negative n (%)	Total	<i>p</i> -value
Excellent	11(21.6)	9 (17.7)	2 (3.9)	22 (43.1)	0.2986
Good	13 (25.5)	5 (9.8)	1 (2)	19 (37.3)	
Poor	4 (7.8)	3 (5.9)	3 (5.9)	10 (19.6)	
Total	28 (54.9)	17 (33.3)	6 (11.8)	51 (100)	
Knowledge of IPT		Practice			
	Excellent n (%)	Good <i>n</i> (%)	Poor <i>n</i> (%)		
Excellent	4 (7.8)	8 (15.7)	8 (15.7) 10 (19.6)		0.7352
Good	7 (13.7)	6 (11.8)	6 (11.8)	19 (37.2)	
Poor	2 (3.9)	4 (7.8)	4 (7.8)	10 (19.6)	
Total	13 (25.5)	18 (35.3)	20 (39.2)	51 (100)	
Attitude		Practic	e		
Positive	12 (23.5)	6 (11.8)	10 (19.6)	28 (54.9)	0.0185
Neutral	1 (2)	9 (17.6)	7 (13.7)	17 (33.3)	
Negative	0	3 (5.9)	3 (5.9)	6 (11.8)	
Total	13 (25.5)	18 (35.3)	20 (39.2)	51 (100)	

The findings with regard to doctors' attitudes towards IPT were consistent with a study where the mean attitude score of healthcare workers towards IPT was 80.6%, with 69.2% having a positive attitude, 26.9% a neutral attitude score, and 3.9% a negative attitude score<sup>19</sup> Healthcare workers' favourable attitude (60%) towards IPT provision was also reported in a study conducted in Indonesia.<sup>26</sup> In the current study, the majority (33; 64.7%) believed they comply with the national and international recommendations of IPT guidelines. Whilst this level of compliance by the doctors with the national and international recommendation guidelines is highly commendable, it could be improved. The attitudes with regard to compliance contrast to those in a study conducted in the Bojanala district of North West province of South Africa, which reported a low overall adherence rate by doctors to the treatment guidelines of 51%.<sup>28</sup> A systematic review of 76 published articles also concluded that doctors generally adhered poorly to clinical practice guidelines,<sup>29</sup> in contrast with the findings of the current study.

Remarkably, most doctors 45 (88.2%) advised their patients on adherence to IPT. Patient adherence was self-reported by 79.9% of patients in Addis Ababa, and this was reported to be associated with healthcare providers giving adequate information to their patients.<sup>30</sup> In contrast, in a previous study conducted in Addis Ababa, patient non-adherence was observed due to insufficient information regarding IPT provided by the healthcare providers.<sup>31</sup> Healthcare providers' adherence to HIV and TB guidelines for treatment and detection of latent TB amongst PLHIV was very poor, and physicians' adherence to guidelines was associated with their experience.<sup>32</sup>

	Received IPT training			
Knowledge of IPT	Yes n (%)	No n (%)	Total n (%)	<i>p</i> -value
Excellent	7 (13.7)	15 (29.4)	22 (43.1)	0.1323
Good	5 (9.8)	14 (27.4)	19 (37.3)	
Poor	0	) 10 (19.6)		
Total	12 (23.5)	39 (76.5)	51 (100.0)	
Attitude:				
Positive	7 (13.7)	21 (41.2)	28 (54.9)	1.0000
Neutral	4 (7.8)	13 (25.5)	17 (33.3)	
Negative	1 (2)	5 (9.9)	6 (11.8)	
Total	12 (23.5)	39 (76.5)	51 (100)	
Practice:				
Excellent	6 (11.8)	6 (11.8) 7 (13.7)		0.0185
Good	2 (3.9)	16 (31.4)	18 (35.3)	
Poor	4 (7.8)	16 (31.4)	20 (39.2)	
Total	12 (23.5)	39 (76.5)	51 (100.0)	

 Table 9: Relationship between doctors trained on IPT and knowledge, attitude and IPT practice

There was no statistically significant association (p = 0.2986) between the knowledge of doctors and their attitudes towards IPT provision in this study. In contrast, another study indicated that healthcare providers' attitudes had a significant association with knowledge (p < 0.001).

There was no statistically significant association between the knowledge and practice of doctors (p = 0.735). Only four (7.8%) doctors had excellent knowledge coupled with excellent practice. Ten (19.6%) doctors with excellent knowledge had poor practice levels. There is strong evidence that TB-related training is a positive predictive factor for practice.<sup>33</sup>

The doctors' attitude had a highly significant association with the level of doctors' practice behaviour towards IPT provision. As the level of attitude increases, the practice of IPT amongst doctors in Odi District Hospital improves. Hence training and awareness programmes should be emphasised, to increase the positive attitude of doctors towards IPT implementation as supported by Durovin *et al.*, who conducted a TB/HIV study in Rio de Janeiro, the results of which strongly supported the importance of the training and education of staff in health units regarding IPT intervention.<sup>21</sup>

Overall the formal training on IPT had a statistically significant association with the practice of IPT. This finding supports that of an earlier large study, which suggested that training led to an observed rapid increase in IPT implementation in HIV-positive patients.<sup>34</sup>

## Conclusion

Doctors at Odi District Hospital generally had excellent knowledge of IPT, but this was not reflected in their practice, as their mean practice score was just above an average of 50%. Although most doctors were not trained on IPT, their attitude scores were high; only 12 (23.5%) of the doctors were trained on the IPT programme and implementation. The finding that healthcare providers' lack of information (35%) did not comply with the national and international IPT recommendations was evident in other studies.<sup>31</sup> These could be the reasons for the low level of IPT provision at Odi District Hospital. As a result, it can be concluded that doctors in Odi District Hospital, irrespective of their category, need formal training specifically in IPT and its successful implementation at the hospital.

## Limitation of the study

The study has a descriptive design and does not attempt to generalise the findings to populations outside the study participants. Therefore, the findings of this study could not be generalised beyond the participants at Odi Hospital. The results of this study may not necessarily apply to other contexts although the authors believe that this may be the case for most district hospitals. This research did not explore other means of preventing TB such as vaccines.

## **Disclosure statement**

No potential conflict of interest was reported by the authors.

#### ORCID

AT Abdulrazaak D http://orcid.org/0000-0002-8735-8982

#### References

- 1. World Health Organization. WHO fact sheet; global tuberculosis report 2014. Geneva: WHO; 2014.
- World Health Organization. WHO 2016 global report on country profiles for the 30 high- burden countries for tuberculosis. Geneva: WHO; 2016.
- World Health Organization. WHO three I's meeting. Intensified Case Finding, Isoniazid Preventive Therapy and TB Infection Control for people living with HIV. Report of a joint WHO HIV/AIDS and TB Department Meeting, 2–4 April. Geneva: WHO; 2008.
- Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLOS One. 2012;7 (3):e34156. https://doi.org/10.1371/journal.pone.0034156
- Naidoo K, Padayatchi N, Karim QA. HIV-associated tuberculosis. Clin Dev Immunol. 2011: 585919. doi:10.1155/2011/585919.
- Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;5 (4):298–304.
- World Health Organization. Toward universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report. Geneva: WHO; 2010.
- National Department of Health. South Africa. Guidelines for tuberculosis preventive therapy among HIV-infected individuals in South Africa. 2013.
- Churchyard GJ, Gavin K, Katherine L, et al. Trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370: 301–310. doi:10.1056/NEJMoa1214289.
- Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365: 11–20. 9.
- Godfrey-Fausett P. Policy statement of preventive therapy against tuberculosis in people living with HIV. Report of a meeting held in Geneva, 18–20 February 1998. World Health Organization, Global Tuberculosis Programme and UNAIDS [Internet]. Geneva: WHO; 1998. Available from: http://whqlibdoc.who.int/hq/1998/WHO\_TB\_ 98.255.pdf.
- Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004–2006. J Acq Immune Defic Synd. 2010;54(1):71–77.
- World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013.
- 14. Odi District Hospital Records. (2015.
- Bateman C. Doctor IPT ignorance contributing to TB epidemic: study. SAMJ. 2011;101(2):88–90.
- Churchyard GJ. Doctor IPT ignorance contributing to TB epidemic study. SAMJ. 2011;104(5):88–90.
- 17. Teklay G, Teklu T, Legesse B, et al. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in northern

Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16:3525–3528.

- Bloom BS, Engelhart MD, Fusrt EJ, et al. Taxonomy of educational objectives: the classification of educational goals. handbook 1: cognitive domain. New York: David McKay Company; 1959.
- Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med. 2013;19(3):266–72.
- 20. Tikuye AM. Knowledge, attitudes and practices of health care providers towards isoniazid preventive therapy provision in Addis Ababa, Ethiopia [Master's of Public Health dissertation]. University of South Africa; 2013.
- Durovni B, Cavalcante SC, Saraceni V, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24(Supplement 5):S49–S56.
- Hiransuthikul N, Hiransuthikul P, Nelson EK, et al. Physician adherence to IPT. South-east Asian J Trop Med Public Health. 2005;36 (5):1208–1215.
- 23. Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010;24(5):45–48.
- 24. Date AA, Vitoria M, Granich R, et al. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull WHO. 2010;88(4):253–259.
- Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12 (5):744–751.
- 26. Charalambous S, Grant AD, Innes C. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS. 2010;24(Suppl 5): S5–S13.

- Sutiono HO, Soeroto AY, Lestari BW. Knowledge, attitude and practice survey among nurses in Dr hasan sadikin general hospital towards tuberculosis human immunodeficiency virus collaboration program. Althea Med J. 2016;3(1):85–92.
- Adedeji AR, Tumbo J, Govender I. Adherence of doctors to a clinical guideline for hypertension in bojanala district, north west province, South Africa. PHCFM. 2015;7(1):776. doi:10.4102/phcfm.v7i1.776.
- Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–1465.
- Mindachew M, Deribew A, Tessema F, et al. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health. 2011;11:1–7.
- 31. Mindachew M, Deribew A, Memiah P, et al. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17:26. doi:10.11604/pamj.2014.17.26.2641
- Saraceni V, King BS, Golub JE, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de janeiro city, Brazil. Int J Tuberc Lung Dis. 2008;12:769–772.
- 33. Gigaw GD, Alemu ZA, Tihahun K. Assessment of knowledge and practice of health workers towards tuberculosis infection and control and associated factors in public health facilities of Addis Ababa, Ethiopia: a cross-sectional study. Arch Public Health. 2015;73:15–24.
- Bristow CC, Larson E, Vilakazi-Nhlapo AK, et al. Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa. Int J Lung Dis. 2012;16(8):1020–1022.

Received: 16-12-2017 Accepted: 13-11-2018

## **Appendix A: Questionnaire**

# A. Demographic information

1.Gender		Male					Female	e		
2.Age (years)										
3.Marital status	Single		Married		V	Vidowed		Di	ivorced	
4.Professional categor	y Community	service medical offic	er	Medical officer		Sessional do	ctor	Registra	r	Specialist
									-	
5.Years of experience	as a medical docto	er:								
6. Have you been train	ned on TB and HIV	collaborative activit	ies?	Yes				No		
7. Have you been train	ned specifically on	IPT?					No			Yes

## B. Knowledge about IPT

Please tick or circle one of your best answers as appropriate to the specific item of the question.

12. Do you think current pregnancy is a contraindication for starting IPT?

8. In your opinion, do you think IPT reduces the risk of TB infection in HIV-positive patients?	Yes			No	
9. Which combination of TB screening symptoms do you use to identify whether PLHIV are eligible for	or IPT or	1. Curr	ent cough, rash	, fever, weight lo	ss.
not?		2. Feve	Fever, current cough, rash, night sweats.		
		3. Curr loss.	ent cough, feve	er, night sweats, v	veight
		4. Weig	ght loss, nausea	ı, fever, rash.	

10. Do you think chest radiography is a requirement for screening PL	HIV for IPT eligibility?	Yes		No	
11.In your opinion, who is eligible to receive IPT	1. All	infants of mother	with pulmonar	y TB.	
	2. All	infants < 5years i	n contact with s	smear-positive TB	patient.
	3. All	HIV positive patie	nts who do not	have active TB.	
	4. All	above cases.			
	5. On	ly 2 and 3.			

Yes

No

4. Pharmacy refill data.

13. Can IPT be used as secondary prophylaxis for people with past history of TB?	Yes	No
14. Which is the best TB preventive drug?		1. Isoniazid (INH)
		2. Rifampicin (RIF)
		3. Pyrizinamide (PZA)
		4. None
15. What is the INH drug dose used for chemotherapy to prevent TB in adults living with	h HIV?	1. 100 mg/day
		2. 200 mg/day
		3. 300 mg/day
		4. 150 mg/day
		5. None of the above.
16. How do you assess whether your patients are adherent to IPT or not?		1. Patient self-report.
		2. Detailed interview.
		3. Pill counts.

5. -6. -

## C. Attitude towards IPT efficacy and provision

Please select only one response that best suits among the Likert scale measurement of your attitude.

<ul> <li>18. IPT is effective in reducing TB incidence and mortality among PLHIV.</li> <li>19. PLHIV who do not have current cough, fever, weight loss or night sweats are unlikely to have active</li> </ul>	TB and should b	1. 2. 3. 4. 5. De offered IPT. 1. 2.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree. Strongly agree. Agree. Undecided
		4. 5.	Disagree. Strongly disagree.
20. IPT should be given to all eligible PLHIV irrespective of their immune status.		1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
21. After excluding active TB, IPT won't significantly increase the risk of developing INH resistance.		1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
22. Children < 1year of age should be provided with IPT if they have a household contact history with	a TB case.	1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
23. Pregnancy is not a contraindication for IPT provision.		1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
24. Past history of TB (> 2 years) is not a contraindication for IPT provision.		1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.

2. Fear of developing side effects.

25. The longer the duration of IPT (> 6 months), the longer the patient stays free from TB.		1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
26. On overall, do you agree that you are complying with the national and international IPT recommenda	ations?	1. 2. 3. 4. 5.	Strongly agree. Agree. Undecided. Disagree. Strongly disagree.
		•	
27. If not agreeing to the above, mention your major beliefs preventing you from complying with the rec	commendations.	1.          2.          3.          4.          5.	

# D. Practice on IPT provision

10

28. Do you use the TB screening tool (algorithm) to identify PLHIV eligible for IPT?				1. 2. 3.	Yes, always. Yes, sometimes. No.
29. Do you encourage PLHIV to start IPT once they are eligible?				1. 2. 3.	Yes, always. Yes, sometimes. No.
30. Do you provide INH for eligible HIV-positive patients?				1. 2. 3.	Yes, always. Yes, sometimes. No.
31. If your answer for Q30 is yes, how many of the 10 newly enrolled HIV-positive patients started year?	IPT in the la	st one – IP	 ग.	of 10 p	atients started
32. If you are providing IPT for your patients, how frequently do you supply the INH drug?			1. D. 2. W 3. M 4. Ev 5. Pe	aily. /eekly. onthly. /ery 3 n er patier	nonths. nt's convenience.
33. Do you advise clients on IPT to adhere to their treatment?				1. 2. 3.	Yes, always. Yes, sometimes. No.
34. Do you monitor/manage clients with INH drug toxicity?				1. 2. 3.	Yes, always. Yes, sometimes. No.
35. If your answer to Q30 is 'No', what hinders you from putting the patient on IPT? (multiple answ possible)	wers are	1. Fea 2. Fea	r of INH res r of develo	sistance ping sid	le effects.

	3. 4. 5. 6. 7. 8. 9. 10. 11.	Difficult to exclude active TB. Not sure of the benefit of IPT. No adequate knowledge of IPT. Patient refuses to take IPT. Patient's poor adherence. TST is unavailable. Chest X-ray is unavailable. INH is unavailable. Other, specify
36. Did you experience INH stock out in the last one year?		<ol> <li>Yes, for less than one month.</li> <li>Yes, for more than one month.</li> <li>No shortage.</li> <li>N/A</li> </ol>
37. Please mention the major interventions required for the successful implementation of	IPT in your area.	1.          2.          3.          4.          5.